Neuralink's PRIMA Vision Chip Available in Europe for Age-Related Eye Disease
What happened
Max Hodak, former president and co-founder of Neuralink, announced that the PRIMA vision-restoring chip is commercially available in Europe for patients with geographic atrophy, an advanced form of age-related macular degeneration. The company is also applying the device to Stargardt disease. The chip is currently undergoing clinical trials at Sydney Eye Hospital.
From techcrunch.com
Why it matters
The commercial availability of PRIMA in Europe for treating geographic atrophy expands the medical applications of Neuralink's technology. Hodak outlined that the company views its work as part of a broader pursuit of novel brain-computer interface medical applications.
From techcrunch.com
Who's involved
Who could feel it
Possible knock-on effectsThese are possibilities Brind reasoned out, not predictions, and not advice. Most are not stated in any report.
- NeuralinkSpeculative
Neuralink could see increased revenue and market position from the commercial availability in Europe.
- Sydney Eye HospitalSpeculative
Sydney Eye Hospital might see increased demand for specialized ophthalmic services due to the ongoing clinical trial.
- EuropeSpeculative
Europe's medical technology market could see changes in demand for advanced vision-restoring devices.